Citizens Raises Price Target for Sutro Biopharma (STRO) Due to Strong Pipeline and Lead Program
On April 23, Citizens raised its price target for Sutro Biopharma (NASDAQ: STRO) from $35 to $41 while maintaining an 'Outperform' rating. The firm cited strong preclinical results across the company's pipeline, particularly in its lead program STRO-004, and highlighted potential best-in-class data by mid-2026.
Tickers: $STRO
Topics: Analyst Upgrades Biopharma Pipeline Progress Price Target